FAIM Enhances the Efficacy of Mesenchymal Stem Cell Transplantation by Inhibiting JNK-Induced c-FLIP Ubiquitination and Degradation

Jinyong Chen, Feng Liu, Wangxing Hu, Yi Qian, Dilin Xu, Chenyang Gao, Zhiru Zeng, Si Cheng, Lan Xie, Kaixiang Yu, Gangjie Zhu, and Xianbao Liu

1Department of Cardiology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China
2Cardiovascular Key Laboratory of Zhejiang Province, Hangzhou 310009, China
3Department of General Intensive Care Unit, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China
4Department of Rheumatology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China

Correspondence should be addressed to Xianbao Liu; liuxb@zju.edu.cn

Received 15 July 2022; Revised 28 August 2022; Accepted 6 September 2022; Published 0 September 2022

Academic Editor: Shao-Wei Li

Background. The poor survival rates of transplanted mesenchymal stem cells (MSCs) in harsh microenvironments impair the efficacy of MSCs transplantation in myocardial infarction (MI). Extrinsic apoptosis pathways play an important role in the apoptosis of transplanted MSCs, and Fas apoptosis inhibitory molecule (FAIM) is involved in regulation of the extrinsic apoptosis pathway. Thus, we aimed to explore whether FAIM augmentation protects MSCs against stress-induced apoptosis and thereby improves the therapeutic efficacy of MSCs.

Methods. We ligated the left anterior descending coronary artery (LAD) in the mouse heart to generate an MI model and then injected FAIM-overexpressing MSCs (MSCs FAIM) into the peri-infarction area in vivo. Moreover, FAIM-overexpressing MSCs were challenged with oxygen, serum, and glucose deprivation (OGD) in vitro, which mimicked the harsh microenvironment that occurs in cardiac infarction.

Results. FAIM was markedly downregulated under OGD conditions, and FAIM overexpression protected MSCs against OGD-induced apoptosis. MSCs FAIM transplantation improved cell retention, strengthened angiogenesis, and ameliorated heart function. The antiapoptotic effect of FAIM was mediated by cellular-FLICE inhibitory protein (c-FLIP), and FAIM augmentation improved the protein expression of c-FLIP by reducing ubiquitin–proteasome-dependent c-FLIP degradation. Furthermore, FAIM inhibited the activation of JNK, and treatment with the JNK inhibitor SP600125 abrogated the reduction in c-FLIP protein expression caused by FAIM silencing.

Conclusions. Overall, these results indicated that FAIM curbed the JNK-mediated, ubiquitination–proteasome-dependent degradation of c-FLIP, thereby improving the survival of transplanted MSCs and enhancing their efficacy in MI. This study may provide a novel approach to strengthen the therapeutic effect of MSC-based therapy.

1. Introduction

Mesenchymal stem cells (MSCs) transplantation has been shown to be safe and beneficial in the treatment of myocardial infarction (MI) due to the low immunogenicity, multidirectional differentiation ability, and robust paracrine effects of these cells [1, 2]. Several studies have revealed that the main factor that impairs the therapeutic efficacy of MSCs transplantation is the poor survival rate of transplanted cells [3], which is caused by cell death induced by a harsh microenvironment and the limited self-renewal rates of MSCs [4]. A previous study reported that Fas-FasL interactions have a significant effect on death receptor (DR) activation in implanted MSCs, and that inhibiting this interaction by recombinant Fas/Fc protein treatment improves cell retention and restores cardiac function [5], suggesting that extrinsic apoptosis pathways play an important role in transplanted MSCs apoptosis and that intervening in these
pathways by genetic modification may be a new strategy to augment the longevity of transplanted MSCs.

Originally identified as an inhibitor of Fas signaling in B-cell receptor-activated lymphocytes [6], Fas apoptosis inhibitory molecule (FAIM) plays an essential role in apoptosis, metabolism, cell growth, and tumorigenesis [7]. Studies have revealed two splice variants of FAIM, and the short variant is ubiquitously expressed in multiple cell types [8–10]. Increasing evidence indicates that FAIM exerts an antipapoptotic effect on thymocytes and hepatocytes by suppressing T-cell receptor (TCR) signaling or DR signaling [11, 12]. FAIM has been implicated in the regulation of heat- and oxidative stress-induced cell death, and FAIM knockout cells exhibit impaired resistance to cell death induced by stress [13]. A recent study reported that FAIM facilitates cell proliferation by suppressing autophagy [14]. We therefore hypothesized that FAIM might be an excellent candidate to promote MSCs survival and optimize the abilities of MSCs in a hostile ischemic environment.

Cellular FLICE inhibitory protein, also known as c-FLIP, is a strong regulator of the extrinsic apoptosis pathway and competitively inhibits the binding of caspase-8 with FADD, thus avoiding the activation of caspase-8 [15, 16]. c-FLIP expression is markedly decreased in thymocytes and hepatocytes in the absence of FAIM [17]. To date, however, the underlying mechanisms linking FAIM to c-FLIP expression remain unclear, necessitating further exploration.

In this study, we discovered that FAIM overexpression promoted MSCs survival and enhanced their therapeutic effect in MI. The potential mechanisms involve reducing the ubiquitination and degradation of c-FLIP mediated by impairing JNK activation. Our results provide new insights and alternative treatment strategies for stem cell transplantation.

2. Materials and Methods

2.1. Cell Culture and Characterization. Mouse bone marrow-derived MSCs were purchased from Procell (Wuhan, China). Cells were cultured in low-glucose DMEM (#C11885500BT, Gibco, CA, USA) supplemented with 10% fetal bovine serum (FBS) (#10270-106, Gibco) and 100 U/ml penicillin/streptomycin (PS) (#15140-122, Gibco) in a 5% CO2 humidified atmosphere at 37°C.

MSCs were characterized by flow cytometry to analyze the expression of membrane markers with a mouse MSCs surface marker assay kit (#MUXMX-09011, Cyagen Biosciences, Suzhou, China). In brief, MSCs were digested with trypsin (Genom Bio, Hangzhou, China) and resuspended in Hank’s balanced salt solution (HBSS) (Genom Bio.). Subsequently, the single-cell suspensions were incubated with cell surface marker antibodies at 4°C for 30 min (mesenchymal surface markers: Sca-1, CD29, CD44, and CD90; hematopoietic stem cell marker: CD117; endothelial cell marker: CD31; and isotype-matched control). After being washed with HBSS, the MSCs were incubated with fluorescence-conjugated secondary antibodies for another 30 min. Surface marker expression was analyzed with an LSRFortessa flow cytometer (BD, USA). The MSCs were positive for CD29, CD44, CD90, and Sca-1 and negative for CD31 and CD117, and the MSCs were fusiform and arranged in a swirled pattern (Supplementary Figure S1(a)-1(b)).

2.2. Lentivirus Infection. Recombinant lentiviruses expressing mouse FAIM-S labeled with GFP and Flag (GFP-FAIM) or mouse c-FLIP labeled with GFP (GFP-FLIP) and empty lentivirus labeled with GFP (GFP-Vec) were provided by GeneChem (Shanghai, China). MSCs were transduced with lentiviruses (MOI = 50) overnight with HitransG A (GeneChem, Shanghai, China) after being seeded in flasks. Then, the virus-containing supernatants were replaced with fresh medium for further culture. The infection efficiency was determined by measuring the expression of the target gene and the fluorescence of GFP.

2.3. siRNA Transfection. Small interfering RNA (siRNA) oligonucleotides targeting mouse FAIM (si-FAIM) or mouse c-FLIP (si-FLIP) and scramble siRNA (si-Scr) were synthesized (Tsingke, Hangzhou, China) and transfected into MSCs with RNAiMax reagent (#13778-150, Invitrogen, CA, USA). Twenty-four hours after transfection, the transfection efficiency was measured by Western blotting. The siRNA sequences are listed in Table 1.

2.4. Cell Apoptosis Model. To simulate the microenvironment of the ischemic myocardium, a glucose/serum-deprived/hypoxia-induced apoptosis model (OGD) and an H2O2-induced apoptosis model were established as previously described [18]. For the OGD model, forty-eight hours after lentivirus infection, MSCsVec (MSCs infected with vector) or MSCsFAIM (MSCs infected with murine FAIM) were washed with PBS and cultured with glucose-free DMEM under hypoxic conditions (0.3% O2) for an additional 12 h until they were harvested. An H2O2-induced apoptosis model was also used in this study. In brief, after transfection with lentivirus, MSCs were challenged with 1 mM H2O2 in glucose-free DMEM for 2 h until they were harvested.

2.5. TUNEL Assays. TUNEL assays were carried out using a TUNEL staining kit (#C1090, Beyotime, Shanghai, China). In brief, cells were fixed in 10% formalin and permeabilized with 0.5% Triton X-100, followed by incubation with TUNEL staining reagent at 37°C in the dark for 1 hour. Additionally, nuclei were stained with Hoechst 33258 (#H3569, Thermo Fisher, CA, USA). Fluorescence images were acquired, and the apoptotic rates were calculated as the percentages of TUNEL-positive cells.

2.6. Annexin V/Propidium Iodide (PI) Staining. Annexin V/PI staining was carried out using an Annexin V-APC/PI apoptosis kit (#70-AP107, Liankebio, Hangzhou, China). Brieﬂy, the culture medium was collected, and cells were digested with trypsin. The two components were then mixed and centrifuged. Then, the supernatant was discarded, and ı× binding buffer was added to resuspend the MSCs. The single-cell suspensions were incubated with an Annexin V-APC and PI mixture for 15 min at room temperature and then quantified with an LSRFortessa flow cytometer. The
apoptosis rate was calculated as the sum of the percentages of Annexin V+/PI- cells and Annexin V+/PI+ cells.

2.7. RNA Analysis. Total RNA was isolated using TRIzol reagent (#15596-018, Invitrogen) and reverse-transcribed into cDNA with PrimeScript RT Master Mix (#RR036A, TaKaRa, Beijing, China). For qRT–PCR, cDNA was amplified using TB Green Premix Ex Taq™ (#RR420A, TaKaRa) on a LightCycler 480 system (Roche, USA). The mRNA expression levels were determined using the 2−ΔΔCt method, and the results were normalized to β-actin. The primer sequences used for qRT–PCR are listed in Table 2.

2.8. Western Blotting. Whole-cell lysate was isolated using RIPA buffer (#P0013B, Beyotime) supplemented with a 1× protease and phosphatase inhibitor cocktail mixture (#78442, Thermo Fisher), and the total protein concentration was quantified with a BCA assay kit (#FD200, Fude Bio- logical, Nanjing, China). Proteins were separated by SDS–PAGE and then transferred onto PVDF membranes. After blocking with 5% skim milk (#LP0031B, Thermo Fisher), the membranes were incubated overnight at 4°C with the membranes were incubated overnight at 4°C with the specific primary antibodies listed in Table 3, followed by HRP-linked secondary antibody incubation. Finally, the proteins were detected by an Amersham ImageQuant 800 Western blot imaging system using ECL Western blotting reagent (#15596-018, Invitrogen) and reverse-transcribed into cDNA with PrimeScript RT Master Mix (#RR036A, TaKaRa, Beijing, China).

2.9. Mouse MI Model and MSCs Transplantation. Animal breeding, maintenance, and procedures were performed in accordance with the Guide for the Care and Use of Laboratory Animals published by the NIH and approved by the Animal Use Committee of Zhejiang University.

A mouse MI model was established in 10- to 12-week-old male C57BL/6J mice (23-26 g, Hangzhou Medical College Animal Research Center, Hangzhou, China) by left anterior descending coronary artery (LAD) ligation. Then, MSCsFAIM or MSCs Vec (1 × 10^5 cells in 20 μl of DMEM per mouse) were immediately transplanted into the border zone of the ischemic area by intramyocardial injection. Control mice were injected with an equivalent volume of DMEM.

2.10. Echocardiography. Transthoracic echocardiography was performed to evaluate cardiac function on days 0, 3, 7, 14, and 28 after MI surgery. Mice were anesthetized with 2% isoflurane in 95% O2. Serial B-mode and M-mode images were obtained using a Vevo® 2100 ultrasound system (Visual Sonics, Canada), followed by cardiac function analysis using Vevo® LAB software (version 3.1.0).

2.11. Sirius Red Staining. Mice were euthanized by cervical dislocation after being injected with sodium pentobarbital. The hearts were harvested, fixed with 10% formalin, embedded in paraffin, and subsequently sectioned into 3 μm slices. The slices were stained with Sirius Red (#SBJ-0294, SenBeijia Biological, Nanjing, China). The images were quantitatively analyzed using ImageJ software (NIH, USA). The infarct size was calculated as follows: infarct size = [(endocardial + epicardial circumference of the infarct area)/(endocardial + epicardial circumference)] × 100%.

2.12. Immunofluorescence Staining. OCT-embedded hearts were sectioned in a cryostat at a thickness of 7 μm. The slices were fixed with 10% formalin for 10 min, permeabilized with 0.5% Triton X-100 for 15 min, and blocked with 3% BSA (#B265993, Aladdin, Shanghai, China) for 30 min. Subsequently, overnight incubation was performed with the specific primary antibodies listed in Table 4, followed by incubation with Alexa Fluor-conjugated secondary antibody. Nuclei were stained with DAPI mounting medium (#H-1200-10, Vector, CA, USA).

2.13. Tube Formation Assays. Tube formation assays were conducted to evaluate the angiogenic potential of MSCs in response to different treatments. Human umbilical vein endothelial cells (HUVECs) were digested, counted, and resuspended in different conditioned media. Then, single-cell suspensions of the HUVECs were seeded into 96-well plates (1.2 × 10^4 cells per well) coated with 50 μl of solidified Matrigel (#354230, Corning, MA, USA) and cultured for 6 h under standard conditions. Images were captured with Leica DM IL LED microscopes, and the branch points and capillary lengths were quantified with ImageJ software using the angiogenesis analyzer plugin.

2.14. Cycloheximide (CHX) Chase Assay. To evaluate protein stability, MSCs were treated with 10 μg/ml CHX (#S7418, Selleck) to arrest c-FLIP protein biosynthesis under hypoxic conditions for 0 h, 3 h, and 6 h. After the MSCs were harvested, c-FLIP protein expression was assessed by Western blotting.

### Table 1: siRNA sequences.

| siRNA name | Sense | Antisense |
|------------|-------|-----------|
| si-FAIM    | GGAUAUCCAUACCUCUATT | AUGAGGGUAGGUAAUCCTT |
| si-c-FLIP  | CAAGAUGGCCCAAGAUGTT | UUGUUGGGGCAUUCUUGT |
| si-scramble| ACGUGACACGUUCCGAGAATT | |

### Table 2: qRT–PCR primer sequences.

| Target gene | Primer name | Sequence (5′→3′) |
|-------------|-------------|-----------------|
| β-actin     | Forward     | GGTGGGAATGGTCAGAGG |
|             | Reverse     | GTACATGCGTGGGTGTTGA |
| FAIM        | Forward     | ATGGGACACATCGAGGCAAG |
|             | Reverse     | TCCAGCGTGTACTGTATGC |
| c-FLIP      | Forward     | ACACAGGCGAGGCAGAAGATA |
|             | Reverse     | TGGCTCTTTACTTTCGCCATT |
2.15. Protein Degradation and Ubiquitination Assays. To examine protein degradation, MG132 (10 μM, #HY-13259, MCE, Shanghai, China) and chloroquine (CQ, 50 nM, #HY-17589A, MCE) were used to inhibit the ubiquitin–proteasome and autophagy pathways, respectively. Cells were incubated with MG132 or CQ for the indicated times before being harvested, and c-FLIP protein expression was assessed by Western blotting.

For the ubiquitination assay, MSCs were treated with 10 μM MG132 under hypoxic conditions for 6 h before being harvested for immunoprecipitation. The lysates were incubated with anti-FLIP antibodies (#56343, CST, MA, USA) or normal rabbit IgG (#2729, CST), bound to magnetic protein A beads (Bio-Rad), washed thoroughly, and eluted by boiling in 2× loading buffer, followed by Western blotting to examine the level of ubiquitin bound to the c-FLIP protein.

2.16. Immunoprecipitation. Immunoprecipitation was performed as previously described [19]. Briefly, MSCs were lysed with NP-40 cell lysis buffer (#P0013F, Beyotime) supplemented with a 1× protease phosphatase inhibitor cocktail mixture, 10 mM N-ethylmaleimide (NEM) (# HY-D0843, MCE), and 1 mM EDTA. In total, 10% of the lysates was kept as input, and the remaining samples were used for immunoprecipitation. Rabbit monoclonal anti-FLIP antibodies (1:100, #56343, CST) or normal rabbit IgG was incubated with magnetic protein A beads (#1614013, Bio-Rad) for 1 h at room temperature. The supernatant was discarded, and the bead–antibody complexes were washed 3 times with lysis buffer. Then, the bead–antibody complexes were incubated overnight at 4°C with the cell lysates mentioned above. The bead–antibody–protein immunocomplexes were washed 3 times with lysis buffer and then boiled in loading buffer with SDS at 98°C for 5 min to elute the proteins from the beads. Immunoblotting was performed to analyze the ubiquitin levels.

2.17. Statistical Analysis. Representative experiments were repeated at least three times, and the results are depicted as the mean ± standard deviation (SD). Statistical differences between two sets of data were analyzed by Student’s t test, and multiple groups were compared using one-way ANOVA with Tukey’s posttest. All statistical analyses and graphing were performed with GraphPad Prism 8 software. Differences for which \( P < 0.05 \) were considered statistically significant.

3. Results

3.1. FAIM Promoted the Survival of MSCs In Vitro and In Vivo. FAIM expression was found to be upregulated in SRT1720-pretreated MSCs, and FAIM knockdown abolished the protective effects of SRT1720 on MSCs in our previous study [20]. Thus, we speculated that FAIM may have an important effect on the apoptosis of transplanted MSCs. To explore this hypothesis, two cell apoptosis models were used in vitro to mimic ischemia or ROS generation in the MI microenvironment: the OGD model and the H2O2 model (Supplementary Figure S2). As shown in Figures 1(a) and 1(b), the mRNA and protein levels of FAIM were robustly decreased 6 h before being harvested for immunoprecipitation. The lysates were incubated with anti-FLIP antibodies (#56343, CST, MA, USA) or normal rabbit IgG (#2729, CST), bound to magnetic protein A beads (Bio-Rad), washed thoroughly, and eluted by boiling in 2× loading buffer, followed by Western blotting to examine the level of ubiquitin bound to the c-FLIP protein.
Figure 1: Continued.
Figure 1: FAIM protected MSCs against apoptosis in vitro and in vivo. (a) MSCs were cultured for 12 h under OGD conditions or normoxic conditions, and the mRNA level of FAIM was determined by qPCR and normalized to GAPDH. (b) Immunoblot analysis and densitometric quantification of FAIM protein levels under OGD conditions or normoxic conditions. GAPDH served as a loading control. (c) Annexin V-APC/PI staining was performed, and flow cytometry was used to determine the apoptosis rate. The apoptosis rate was calculated as the sum of the percentages of Annexin V+/PI- cells and Annexin V+/PI+ cells. (d) TUNEL staining after FAIM overexpression followed by OGD stimulation for 12 h (scale bar = 100 μm). Quantitative results are shown on the right. Six visual fields were randomly chosen for each well, the apoptotic index was determined as the percentage of TUNEL-positive nuclei. (e) Cleaved caspase 3 protein expression after FAIM overexpression or vector infection followed by OGD stimulation. The results of densitometric quantitation are shown on the right. (f) Representative images showing GFP immunofluorescence (IF) staining 3 days after LAD ligation followed by MSC transplantation. GFP appears in green, cardiac troponin I (cTnI) in red, and nuclei in blue. (scale bar = 100 μm). Quantitative results are shown on the right (n = 6 for the MSCsVec group and MSCsFAIM group). Data are shown as the mean ± SD. * denotes P < 0.05, **P < 0.01.

3.2. FAIM-Overexpressing MSCs Improved Cardiac Function and Reduced Infarct Size. To evaluate the effect of FAIM overexpression on the improvement in therapeutic effect of MSCs, MSCsVec and MSCsFAIM were transplanted into the peri-ischemic area immediately after MI model construction, and an equivalent volume of DMEM was injected into the ischemic hearts in the control group. Transthoracic echocardiography was conducted on days 3, 7, 14, and 28 after cell transplantation to evaluate cardiac function, and limited the fibrotic area than did the MSCsVec.

3.3. FAIM Regulates the Expression of c-FLIP in MSCs under OGD Conditions. The extrinsic apoptosis pathway, which is mediated by DRs, and the intrinsic apoptosis pathway, which is mediated by mitochondria, are the two main pathways through which apoptosis is induced. Caspase-8 and caspase-9 are the initiating caspases in these two pathways [22]. Several studies have demonstrated that FAIM strongly

by an Annexin V-APC/PI assay. The FAIMOE group showed a robust decrease in the percentage of apoptotic cells (Annexin V-positive) under OGD conditions compared with that of the vector group (Figure 1(c)), and this result was further supported by TUNEL staining (Figure 1(d)). Furthermore, the protein expression of cleaved caspase-3, the critical executioner of apoptosis, was examined by Western blotting. We found that FAIM overexpression significantly attenuated the activation of caspase-3 (Figure 1(e)). To explore the antiapoptotic effect of FAIM on MSCs in vivo, MSCs were marked with GFP and injected into the peri-infarct region immediately after LAD ligation. The MSCs retention rate was assessed by fluorescence microscopy 3 days after engrafment (Supplementary Figure S2). The immunofluorescence results showed that while no significant differences were observed between the two groups of cells (Supplementary Figure S4(a)), more FAIM-overexpressing MSCs (MSCsFAIM) than MSCs infected with vector (MSCsVec) remained in the target tissue (Figure 1(f)). These results strongly suggested that FAIM inhibited caspase-3-dependent apoptosis under hypoxic conditions in vitro and in vivo.
Figure 2: Continued.
inhibits DR signaling and Fas-mediated apoptosis [12]; however, the specific role of FAIM in hypoxia-induced apoptosis is poorly understood. Thus, the protein expression of cleaved caspase-8 and cleaved caspase-9 was determined. As expected, FAIM overexpression reduced the cleavage of caspase-8 but had no significant effect on caspase-9 activation (Figures 3(a) and 3(b)). c-FLIP regulates the activation of caspase-8, and FAIM-deficient hepatocytes exhibit decreased c-FLIP protein expression [17]. Therefore, to test whether c-FLIP is involved in hypoxia-induced apoptosis, and whether FAIM can regulate c-FLIP expression, the protein expression level of c-FLIP was examined after the knockdown or overexpression of FAIM and culture under hypoxic conditions by Western blotting. c-FLIP protein expression was notably decreased in the context of hypoxia, and FAIM overexpression blocked this reduction (Figures 3(c) and 3(d)). Not surprisingly, c-FLIP expression notably declined after FAIM knockdown (Figures 3(e) and 3(f)).

3.4. c-FLIP Is Required for the Antiapoptotic Effect of FAIM under OGD Conditions. The relationship between c-FLIP and FAIM was further confirmed. MSCs overexpressing c-FLIP (MSCs$_{cFLIP}$) were generated by lentivirus infection, whereas MSCs infected with empty lentivirus labeled with GFP (GFP-Vec) served as the negative control (MSCs$_{Vec}$). The efficiency of c-FLIP overexpression was detected by Western blotting (Supplementary Figure S4(d)). FAIM was silenced by siRNA in both MSCs$_{Vec}$ and MSCs$_{cFLIP}$, which was followed by OGD exposure. Upon FAIM silencing, c-FLIP overexpression reduced the percentage of apoptotic MSCs, as shown by Annexin V/PI staining and TUNEL assays (Figures 4(a)–4(d)). Western blotting further confirmed that the protein levels of cleaved caspase-3 were significantly decreased by c-FLIP overexpression (Figures 4(e) and 4(f)). Furthermore, MSCs$_{cFAIM}$ were transfected with either siRNA specific for c-FLIP (si-FLIP) or scrambled siRNA (si-Scr), followed by OGD challenge. Under OGD conditions, c-FLIP

![Figure 2](image-url)
silencing significantly elevated the percentage of Annexin V-positive MSCs (Figures 4(g) and 4(h)) and the protein expression of cleaved caspase-3 (Figures 4(k) and 4(l)), and the results were also confirmed by TUNEL staining (Figures 4(i) and 4(j)). These results indicated that the antiapoptotic effect of FAIM under OGD conditions was at least partially dependent on c-FLIP.

3.5. FAIM Stabilizes c-FLIP Protein in MSCs by Inhibiting Its Ubiquitination. To determine the underlying mechanisms, we examined the mRNA level of c-FLIP and found that FAIM overexpression did not alter the transcript expression of c-FLIP (Figure 5(a)). To reveal whether FAIM posttranscriptionally regulates the expression of c-FLIP, a CHX chase assay was performed to test the change in protein stability of c-FLIP in response to FAIM knockdown and overexpression. We found that FAIM overexpression significantly inhibited the decrease in c-FLIP protein expression (Figure 5(b)), but FAIM knockdown facilitated a reduction in c-FLIP expression in MSCs (Figure 5(c)). These data suggested that the degradation of c-FLIP could be impaired by FAIM.

Autophagy and proteasome-dependent proteolysis are the two main ways by which protein degradation is regulated. Consequently, hypoxia-challenged MSCs were treated with CQ to inhibit the autophagy–lysosome pathway and MG132 to impede the proteasome-dependent pathway. In comparison with that in response to DMSO, the expression of c-FLIP was strongly restored by MG132 but barely affected by CQ (Figure 5(d)). Collectively, these data showed that FAIM upregulates c-FLIP protein expression largely by inhibiting its proteasome-dependent degradation. To further investigate the ubiquitination of c-FLIP, we treated OGD-challenged MSCs with MG132 to arrest the degradation of

![Graph](image-url)
Figure 4: Continued.
c-FLIP without affecting its ubiquitination 6 h before harvesting for analysis. We found that c-FLIP was ubiquitinated under hypoxic conditions, and FAIM overexpression markedly decreased the ubiquitination level of c-FLIP (Figure 5(e)). This result complements our previous finding showing that FAIM modulates c-FLIP expression by inhibiting its ubiquitination–proteasome-dependent proteolysis.

3.6. FAIM Reduces c-FLIP Degradation by Blocking JNK Activation. Phosphorylated JNK has been reported to be upregulated during apoptosis [23] and has also been reported to participate in the degradation of c-FLIP [24]. We hypothesized that the JNK pathway is involved in hypoxia-induced apoptosis, and that FAIM attenuates the degradation of c-FLIP by inhibiting the phosphorylation of JNK. To validate this hypothesis, phosphorylated JNK was assessed by Western blotting. As expected, we found that JNK phosphorylation was strongly inhibited by FAIM in hypoxic MSCs (Figures 6(a) and 6(b)), and FAIM silencing increased this phosphorylation (Figures 6(c) and 6(d)). We further treated FAIM-deficient MSCs with SP600125, a specific JNK inhibitor, and verify its impact on c-FLIP protein expression. We found that SP600125 upregulated c-FLIP protein expression (Figures 6(e) and 6(f)), verifying that FAIM inhibits c-FLIP degradation mainly by blocking JNK activation.

Taken together, our results provide evidence that FAIM inhibits MSC apoptosis by inhibiting the ubiquitination-dependent degradation of c-FLIP, which is mediated by JNK inactivation, thereby improving the efficacy of MSC transplantation (Figure 7).

4. Discussion

In this study, we showed that FAIM was downregulated in MSCs under ischemia-like conditions, including hypoxia and oxidative stress, in vitro. Consequently, we overexpressed FAIM in MSCs and found that FAIM augmentation protected MSCs from apoptosis in a harsh microenvironment. Similarly, we observed improved MSCs survival in a mouse MI model. Furthermore, improvements in cardiac function and a reduced infarction size were detected in the MScsFAIM group 28 days after transplantation, accompanied by increased angiogenesis, suggesting that FAIM augmentation improved the efficacy of MSCs transplantation in a mouse MI model. Mechanistically, our findings demonstrated that the antiapoptotic effect of FAIM is largely dependent on c-FLIP, which suppresses the activation of caspase-8. Next, we found that FAIM had no effect on c-FLIP transcription but altered the protein degradation of c-FLIP. Further experiments demonstrated that FAIM protects c-FLIP from ubiquitination–proteasome-dependent degradation, which is mediated by impaired JNK phosphorylation. These data provide a novel approach to improve the effects of stem cells engraftment on cardiovascular indications.

MI poses a grave threat to the health of elderly individuals, and the loss of cardiomyocytes after MI is the most important cause of poor prognosis [25]. Therefore, remuscularization of the heart is the major focus in this field, and countless efforts have been made to find solutions, including promoting the regeneration of cardiomyocytes, transplanting induced pluripotent stem cell (iPSC)-derived cardiomyocytes, exogenous engrafting of stem cells or their derived exosomes, and the application of novel functional materials such as engineered heart tissues and hydrogels [26–29]. It has been demonstrated that within one week of birth, the hearts of neonatal mice exhibit regenerative activity, and subsequent studies showed that regenerative activity also occurred in neonatal pigs [30, 31]. Exploring the mechanism of cardiomyocyte regeneration and implementing treatments have become important research directions. A recent study reported that cardiac-specific knockout of PTEN facilitated the proliferation and renewal of cardiomyocytes [32]. Moreover, Salvador-siRNA delivered by adeno-associated virus 9 promoted the proliferation of cardiomyocytes after ischemia and reperfusion injury by inhibiting the Hippo pathway, which repressed cardiomyocyte proliferation after MI [33]. However, these studies are still in their early stages, and it could take decades to achieve...
Figure 5: Continued.
clinical translational applications. In addition, engineering materials have provided some new ideas for the treatment of MI [34]. Patches were used to provide mechanical support to improve outcomes in the early days after MI, and subsequent studies reported the development of patches equipped with anti-inflammatory activity, but they could not compensate for the loss of cardiomyocytes [29]. However, the unique physical and electrical properties of the heart make it difficult for simple bioengineering materials to be of great use, and those engineering materials are often functionalized through synergistic application with stem cells or iPSC-derived cardiomyocytes [35, 36]. Taken together, these results highlight the importance of cell-based therapies for MI treatment.

Tremendous improvements in cell-based therapies for MI have been made in recent decades, and these therapies aim to produce a sufficient number of cardiomyocytes to compensate for the loss of viable cardiomyocytes after MI [37]. A variety of cells are used in the treatment of MI, such as human iPSCs (hiPSCs), human embryonic stem cells (hESCs), and the widely used hMSCs [27, 38]. Generating cardiomyocytes from hiPSCs are no longer difficult [39], and this strategy has been applied in porcine MI models [40, 41]. However, there are still many challenges before iPSC-derived cardiomyocytes move to early trials, such as arrhythmias that can result from the injection of cardiomyocytes, the long-term immunosuppressant therapy required due to allogeneic-derived iPSCs, and the purity of the large number of iPSC-derived cardiomyocytes during induced proliferation and differentiation [26]. MSCs are ideal candidates for large-scale application in the clinical treatment of MI. Recent studies have shown that the therapeutic effects of MSCs are mainly exerted through their robust paracrine effects [21, 42], which promote the proliferation and migration of endothelial cells and ultimately improve cardiac angiogenesis and left ventricular function [43]. However, the harsh microenvironment formed by conditions including ischemia, hypoxia, oxidative stress, and inflammation causes massive cell death. A large proportion of engrafted stem cells were reported to perish within 24 h after transplantation [44, 45], making strategies that prolong MSCs lifespan an attractive way to improve the efficacy of MSCs [46]. Our previous study showed that pretreatment with SRT1720 improved the efficacy of MSCs in rodent and

**Figure 5:** FAIM stabilizes the c-FLIP protein in MSCs by inhibiting its ubiquitination. (a) mRNA expression of c-FLIP in MSCsVec and MSCsFAIM challenged with OGD. (b) Representative immunoblots showing c-FLIP protein expression in MSCsVec and MSCsFAIM treated with 10 μM CHX for the indicated times under OGD conditions. The results of densitometric quantitation are shown on the right, and the line chart shows c-FLIP protein levels (normalized to GAPDH) as a percentage of the c-FLIP protein expression of MSCsVec at 0 h (n = 3). (c) Representative immunoblots showing c-FLIP protein levels in MSCsVec and MSCsFAIM treated with 10 μM CHX for the indicated times under OGD conditions. The results of densitometric quantitation are shown on the right (n = 3). (d) Representative Western blotting results showing c-FLIP protein expression after siRNA-mediated knockdown of FAIM or scrambled siRNA administration followed by treatment with chloroquine (CQ, 50 nM) or MG132 (10 μM) under OGD conditions. The results of densitometric quantitation are shown below (n = 3). (e) MSCsVec and MSCsFAIM were treated with MG132 (10 μM) under OGD conditions for 6 h. Whole-cell lysates were immunoprecipitated with anti-FLIP antibodies, followed by immunoblotting with anti-ubiquitin antibodies. The input (10% of the total) was analyzed by Western blotting using anti-FLIP and anti-FAIM antibodies. The data are shown as the mean ± SD. Ns indicates not significant; * denotes P < 0.05; ** P < 0.01.
nonhuman primate MI models by prolonging MSCs survival [20, 47]. Consistent with these findings, our results showed that FAIM augmentation improved implanted MSCs survival and ultimately promoted neovascularization and ameliorated cardiac function.

Two splicing variants of FAIM have been described; the longer variant, FAIM-L, which is exclusively expressed in neural tissue, and the ubiquitously expressed shorter variant, known as FAIM-S [10]. FAIM-L exerts antiapoptotic effects by suppressing TCR signaling or DR signaling [11, 12]. However, to the best of our knowledge, this is the first study to reveal the protective effect of FAIM-L against apoptosis induced by hypoxia. Previous studies reported that c-FLIP expression was perturbed in FAIM-depleted cells [17]. Consistent with these findings, our results showed that the survival effect of FAIM was mainly achieved by restoring c-FLIP expression. However, to date, the effects of FAIM on c-FLIP expression are not fully understood. FAIM has been reported to exert its biological effects by reducing ubiquitination; FAIM was found to reduce the ubiquitination and degradation of XIAP via direct interaction [48], FAIM knockout led to the presentation of ubiquitinated aggregates in the retina [49], and FAIM protects glutaminase C from ubiquitination and induces cancer cell proliferation in lung adenocarcinoma [14]. Here, we found that FAIM could maintain c-FLIP stabilization under hypoxic conditions by protecting c-FLIP from ubiquitination and degradation, thus protecting MSCs from apoptosis.

**Figure 6:** FAIM reduces c-FLIP degradation by blocking JNK activation. (a–b) Immunoblots and densitometric quantitation of phosphorylated JNK and total JNK protein expression in MSCsVec and MSCsFAIM under OGD conditions. (c–d) Western blotting and densitometric quantitation of phosphorylated JNK and total JNK protein expression in MSCsi-scr and MSCsi-FAIM under OGD conditions. (e–f) Phosphorylated JNK, total JNK, and c-FLIP protein expression after siRNA-mediated knockdown of FAIM or scrambled siRNA administration followed by treatment with SP600125 (a JNK inhibitor, 10 μM) or DMSO under OGD conditions. The data are shown as the mean ± SD. Ns indicates not significant; * denotes \( P < 0.05 \); ** \( P < 0.01 \).
c-FLIP, a strong regulator of caspase-8 activation due to the pseudocaspase domain at its C-terminus [50], participates in various cell death pathways, including apoptosis, necroptosis, and autophagy [51, 52]. Recent studies have shown that c-FLIP prevents cells from undergoing apoptosis by impairing p53-mediated PUMA upregulation and caspase-8 activation [53]. However, the functions of c-FLIP are contradictory and depend on its abundance in the death-inducing signaling complex (DISC) [15], which is assembled from Fas, FADD, procaspase 8, and c-FLIP [54]. Low concentrations of c-FLIP in the DISC can cause the formation of a procaspase-8/c-FLIP heterodimer and promote caspase-8 activation [55]. On the other hand, c-FLIP at a high concentration competitively suppresses the assembly of procaspase-8 into the DISC and thus reduces the activation of caspase-8 [56]. In the present study, we demonstrated that high protein expression of c-FLIP inhibited the activation of caspase-8; however, the caspase-8 activation status under low c-FLIP expression levels was not examined because we could not confirm whether the cleavage of procaspase-8 caused by the decrease in c-FLIP protein expression was due to a decrease in inhibition or an increase in activation. Regardless, this does not affect our conclusion that FAIM overexpression reduces MSCs apoptosis by ameliorating the decreased expression of c-FLIP under OGD conditions. In addition, accumulating evidence suggests that c-FLIP is a short-lived protein whose half-life is approximately 3 h [24]. Some studies have shown that the degradation of c-FLIP occurs mainly through the ubiquitin–proteasome pathway [57], and JNK activity may be a critical regulator of c-FLIP protein stability [24]. In agreement with previous findings, we revealed that the protein stability of c-FLIP is closely related to the presence of FAIM, and subsequent experiments showed that FAIM regulates c-FLIP protein stability by impairing JNK phosphorylation, which expands the current knowledge of the protein stability of c-FLIP.

There are some limitations of this study. First, our experimental setting could not completely mimic true clinical conditions. MSCs were injected into the peri-infarct zones immediately after LAD ligation, which is unrealistic in the real world. Second, unbiased analysis was not utilized in this study, and mass spectrometry-based proteomics analysis may be a more accurate way to determine the most predominant protein that regulates the antia apoptotic effects of FAIM in our model. Third, the mechanism by which FAIM regulates JNK activation was not explored in this work.

5. Conclusion

In conclusion, our study demonstrated that FAIM augmentation could effectively promote MSCs survival in vivo and ultimately ameliorate cardiac function and improve the prognosis of MI, providing a novel approach to improve the efficacy of MSC-based therapy.

Abbreviations

MSCs: Mesenchymal stem cells
OGD: Oxygen, serum, and glucose deprivation
MI: Myocardial infarction.
LAD: Left anterior descending coronary artery
FAIM: Fas apoptosis inhibitory molecule
c-FLIP: Cellular-FLICE inhibitory protein
MSCsVec: MSCs infected with vector
MSCsFAIM: MSCs infected with FAIM
MSCsFLIP: MSCs infected with c-FLIP
FADD: Fas-associated via death domain
DR: Death receptor
CHX: Cycloheximide.

Data Availability

The datasets used and/or analyzed to support the findings of this study are included within the article and supplementary information files.

Ethical Approval

All animal experiment protocols were approved by the Medical Ethics Committee of the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this paper.

Authors’ Contributions

X.L. conceived the idea, designed the study, and revised the manuscript. J.C. and F.L. performed most of the experiments and drafted the manuscript. W.H., Y.Q., D.X. and C.G. analyzed and interpreted the data. Z.Z., G.Z., S.C. and K.Y. conducted the animal surgery and echocardiography. L.X. contributed to the immunoprecipitation assay and drew the schematic diagram. All authors read and approved the final manuscript.

Acknowledgments

This work was supported by the National Natural Science Foundation of China [81770252 to X.L.] and the Science and Technology Department of Zhejiang Province Key R&D Program [2021C03097 to J.W. and 2022C03063 to X.L.]. We thank Dr. Xiaoying Chen and Dr. Kaiqi Lv for their kindly guidance and help in animal experiments.

Supplementary Materials

Supplementary Figure S1: characterization of mesenchymal stem cells (MSCs). Supplementary Figure S2: schematic of the in vitro and in vivo experiments. Supplementary Figure S3: FAIM protected MSCs against H2O2-induced apoptosis in vitro. Supplementary Figure S4: identification of FAIM overexpression lentivirus and FAIM siRNA. Supplementary Figure S5: FAIM knockdown facilitated MSCs apoptosis. Supplementary Figure S6: FAIM overexpression reversed the decrease in the proangiogenic capacity of conditioned medium from MSCs induced by OGD. (Supplementary Materials)

References

[1] M. R. Rosen, R. J. Myerburg, D. P. Francis, G. D. Cole, and E. Marbán, “Translating stem cell research to cardiac disease therapies: pitfalls and prospects for improvement,” *Journal of the American College of Cardiology*, vol. 64, no. 9, pp. 922–937, 2014.

[2] I. K. Ko and B. S. Kim, “Mesenchymal stem cells for treatment of myocardial infarction,” *International Journal of Stem Cells*, vol. 1, no. 1, pp. 49–54, 2008.

[3] C. Toma, M. F. Pittenger, K. S. Cahill, B. J. Byrne, and P. D. Kessler, “Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart,” *Circulation*, vol. 105, no. 1, pp. 93–98, 2002.

[4] A. Elsasser, K. Suzuki, S. Lorenz-Meyer, C. Bode, and J. Schaper, “The role of apoptosis in myocardial ischemia: a critical appraisal,” *Basic Research in Cardiology*, vol. 96, no. 3, pp. 219–226, 2001.

[5] O. Ham, S. Y. Lee, B. W. Song et al., “Modulation of Fas-Fas ligand interaction rehabilitates hypoxia-induced apoptosis of mesenchymal stem cells in ischemic myocardium niche,” *Cell Transplantation*, vol. 24, no. 7, pp. 1329–1341, 2015.

[6] T. J. Schneider, G. M. Fischer, T. J. Donohoe, T. P. Colarusso, and T. L. Rothstein, “A novel gene coding for a Fas apoptotic inhibitory molecule (FAIM) isolated from inducibly Fas-resistant B lymphocytes,” *The Journal of Experimental Medicine*, vol. 189, no. 6, pp. 949–956, 1999.

[7] J. Huo, S. Xu, and K. P. Lam, “FAIM: an antagonist of Fas-killing and beyond,” *Cells*, vol. 8, no. 6, p. 541, 2019.

[8] C. Sole, X. Dolcet, M. F. Segura et al., “The death receptor antagonist FAIM promotes neurite outgrowth by a mechanism that depends on ERK and NF-kB signaling,” *The Journal of Cell Biology*, vol. 167, no. 3, pp. 479–492, 2004.

[9] E. Coccia, I. Calleja-Yague, L. Planells-Ferrer et al., “Identification and characterization of new isoforms of human fas apoptotic inhibitory molecule (FAIM),” *PLoS One*, vol. 12, no. 10, article e0185327, 2017.

[10] X. Zhong, T. J. Schneider, D. S. Cabral, T. J. Donohoe, and T. L. Rothstein, “An alternatively spliced long form of Fas apoptosis inhibitory molecule (FAIM) with tissue-specific expression in the brain,” *Molecular Immunology*, vol. 38, no. 1, pp. 65–72, 2001.

[11] J. Huo, S. Xu, and K. P. Lam, “Fas apoptosis inhibitory molecule regulates T cell receptor-mediated apoptosis of thymocytes by modulating Akt activation and Nur77 expression,” *The Journal of Biological Chemistry*, vol. 285, no. 16, pp. 11827–11835, 2010.

[12] M. F. Segura, C. Sole, M. Pascual et al., “The long form of Fas apoptotic inhibitory molecule is expressed specifically in neurons and protects them against death receptor-triggered apoptosis,” *The Journal of Neuroscience*, vol. 27, no. 42, pp. 11228–11241, 2007.

[13] H. Kaku and T. L. Rothstein, “FAIM is a non-redundant defender of cellular viability in the face of heat and oxidative stress and interferes with accumulation of stress-induced protein aggregates,” *Frontiers in Molecular Biosciences*, vol. 7, p. 32, 2020.

[14] T. Han, P. Wang, Y. Wang et al., “AIM regulates autophagy through glutaminolysis in lung adenocarcinoma,” *Autophagy*, vol. 18, no. 6, pp. 1416–1432, 2022.

[15] N. V. Ivanisenko, K. Seyrek, L. K. Hillert-Richter et al., “Regulation of extrinsic apoptotic signaling by c-FLIP: towards targeting cancer networks,” *Trends Cancer*, vol. 8, no. 3, pp. 190–209, 2022.

[16] L. Humphreys, M. Espona-Fiedler, and D. B. Longley, “FLIP as a therapeutic target in cancer,” *The FEBS Journal*, vol. 285, no. 22, pp. 4104–4123, 2018.

[17] J. Huo, S. Xu, K. Guo, Q. Zeng, and K. P. Lam, “Genetic deletion of FAIM reveals its role in modulating c-FLIP expression during CD95-mediated apoptosis of lymphocytes and hepatocytes,” *Cell Death & Differentiation*, vol. 16, no. 7, pp. 1062–1070, 2009.

[18] K. Yu, Z. Zeng, S. Cheng et al., “TPP1 enhances the therapeutic effects of transplanted aged mesenchymal stem cells in infarcted hearts via the MRE11/AKT pathway,” *Frontiers in Cell and Development Biology*, vol. 8, article 588023, 2020.

[19] F. Yang, R. Wu, Z. Jiang et al., “Leptin increases mitochondrial OPA1 via GSK3-mediated OMA1 ubiquitination to enhance therapeutic effects of mesenchymal stem cell transplantation,” *Cell Death & Disease*, vol. 9, no. 5, p. 556, 2018.

[20] X. Liu, D. Hu, Z. Zeng et al., “SRT1720 promotes survival of aged human mesenchymal stem cells via FAIM: a pharmacological strategy to improve stem cell-based therapy for rat
myocardial infarction,” *Cell Death & Disease*, vol. 8, no. 4, article e2731, 2017.

[21] M. Z. Ratajczak, M. Kucia, T. Jadczyk et al., “Pivotal role of paracrine effects in stem cell therapies in regenerative medicine: can we translate stem cell-secreted paracrine factors and microvesicles into better therapeutic strategies?,” *Leukemia*, vol. 26, no. 6, pp. 1166–1173, 2012.

[22] B. A. Carneiro and W. S. El-Deiry, “Targeting apoptosis in cancer therapy,” *Nature Reviews Clinical Oncology*, vol. 17, no. 7, pp. 395–417, 2020.

[23] Y. Fuchs and H. Steller, “Programmed cell death in animal development and disease,” *Cell*, vol. 147, no. 4, pp. 742–758, 2011.

[24] R. P. Wilkie-Granatham, S. Matsuzawa, and J. C. Reed, “Novel phosphorylation and ubiquitination sites regulate reactive oxygen species-dependent degradation of anti-apoptotic c-FLIP protein,” *The Journal of Biological Chemistry*, vol. 288, no. 18, pp. 12777–12790, 2013.

[25] C. W. Tsao, A. W. Aday, Z. I. Almarzooq et al., “Heart disease and stroke statistics-2022 update: a report from the American Heart Association,” *Circulation*, vol. 145, no. 8, pp. e153–e639, 2022.

[26] J. Zhang, R. Bolli, D. J. Garry et al., “Basic and translational research in cardiac repair and regeneration,” *Journal of the American College of Cardiology*, vol. 78, no. 21, pp. 2092–2105, 2021.

[27] Y. W. Liu, B. Chen, X. Yang et al., “Human embryonic stem cell-derived cardiomyocytes restore function in infarcted hearts of non-human primates,” *Nature Biotechnology*, vol. 36, no. 7, pp. 597–605, 2018.

[28] J. H. Jung, G. Ikeda, Y. Tada et al., “miR-106a-363 cluster in extracellular vesicles promotes endogenous myocardial repair via Notch 3 pathway in ischemic heart injury,” *Research in Cardiology*, vol. 116, no. 1, p. 19, 2021.

[29] Y. Yao, A. Li, S. Wang et al., “Multifunctional elastomer cardiac patches for preventing left ventricle remodeling after myocardial infarction in vivo,” *Biomaterials*, vol. 282, article 121382, 2022.

[30] E. R. Porrello, A. I. Mahmoud, E. Simpson et al., “Transient regenerative potential of the neonatal mouse heart,” *Science*, vol. 331, no. 6020, pp. 1078–1080, 2011.

[31] W. Zhu, E. Zhang, M. Zhao et al., “Regenerative potential of neonatal porcine hearts,” *Circulation*, vol. 138, no. 24, pp. 2809–2816, 2018.

[32] T. Liang, F. Gao, J. Jiang et al., “Loss of phosphatase and tensin homolog promotes cardiomyocyte proliferation and cardiac repair after myocardial infarction,” *Circulation*, vol. 142, no. 22, pp. 2196–2199, 2020.

[33] S. Liu, K. Li, L. Wagner Florencio et al., “Gene therapy knockdown of Hippo signaling induces cardiomyocyte renewal in pigs after myocardial infarction,” *Science Translational Medicine*, vol. 13, no. 600, 2021.

[34] V. Sharma, S. K. Dash, K. Govarthanan et al., “Recent Advances in cardiac tissue engineering for the management of myocardium infarction,” *Cells*, vol. 10, no. 10, p. 2538, 2021.

[35] L. Wang, Y. Liu, G. Ye et al., “Injectable and conductive cardiac patches repair infarcted myocardium in rats and minipigs,” *Nature Biomedical Engineering*, vol. 5, no. 10, pp. 1157–1173, 2021.

[36] S. Hinderer, E. Brauchle, and K. Schenke-Layland, “Generation and assessment of functional biomaterial scaffolds for applications in cardiovascular tissue engineering and regenerative medicine,” *Advanced Healthcare Materials*, vol. 4, no. 16, pp. 2326–2341, 2015.

[37] P. Menasche, “Cell therapy trials for heart regeneration—lessons learned and future directions,” *Nature Reviews Cardiology*, vol. 15, no. 11, pp. 659–671, 2018.

[38] E. Marban, “A mechanistic roadmap for the clinical application of cardiac cell therapies,” *Nature Biomedical Engineering*, vol. 2, no. 6, pp. 353–361, 2018.

[39] H. Kempf, C. Kropp, R. Olmer, U. Martin, and R. Zweigerdt, “Cardiac differentiation of human pluripotent stem cells in scalable suspension culture,” *Nature Protocols*, vol. 10, no. 9, pp. 1345–1361, 2015.

[40] L. Gao, Z. R. Gregorich, W. Zhu et al., “Large cardiac muscle patches engineered from human induced-pluripotent stem cell-derived cardiac cells improve recovery from myocardial infarction in swine,” *Circulation*, vol. 137, no. 16, pp. 1712–1730, 2018.

[41] M. Zhao, Y. Nakada, Y. Wei et al., “Cyclin D2 overexpression enhances the efficacy of human induced pluripotent stem cell-derived cardiomyocytes for myocardial repair in a swine model of myocardial infarction,” *Circulation*, vol. 144, no. 3, pp. 210–228, 2021.

[42] K. Zhu, Q. Wu, C. Ni et al., “Lack of remuscularization following transplantation of human embryonic stem cell-derived cardiovascular progenitor cells in infarcted nonhuman primates,” *Circulation Research*, vol. 122, no. 7, pp. 958–969, 2018.

[43] J. Ma, Y. Zhao, L. Sun et al., “Exosomes derived from Akt-modified human umbilical cord mesenchymal stem cells improve cardiac regeneration and promote angiogenesis via activating platelet-derived growth factor D,” *Stem Cells Translational Medicine*, vol. 6, no. 1, pp. 51–59, 2017.

[44] J. V. Terrovitis, R. R. Smith, and E. Marban, “Assessment and optimization of cell engraftment after transplantation into the heart,” *Circulation Research*, vol. 106, no. 3, pp. 479–494, 2010.

[45] M. Mohammadzadeh, R. Halabian, A. Gharehbaghi et al., “Nrf2 overexpression in mesenchymal stem cells reduces oxidative stress-induced apoptosis and cytotoxicity,” *Cell Stress & Chaperones*, vol. 17, no. 5, pp. 553–565, 2012.

[46] L. Li, X. Chen, W. E. Wang, and C. Zeng, “How to improve the survival of transplanted mesenchymal stem cell in ischemic heart?,” *Stem Cells International*, vol. 2016, Article ID 9682757, 14 pages, 2016.

[47] Z. Zeng, K. Yu, W. Hu et al., “SRT1720 pretreatment promotes mitochondrial biogenesis of aged human mesenchymal stem cells and improves their engraftment in postinfarct nonhuman primate hearts,” *Stem Cells and Development*, vol. 30, no. 7, pp. 386–398, 2021.

[48] E. Coccia, L. Planells-Ferrer, R. Badillos-Rodriguez et al., “SIVA-1 regulates apoptosis and synaptic function by modulating XIAP interaction with the death receptor antagonist FAIM-L,” *Cell Death & Disease*, vol. 11, no. 2, p. 82, 2020.

[49] A. Sires, M. Turch-Anguera, P. Bogdanov et al., “FAIM knock-out leads to gliosis and late-onset neurodegeneration of photoreceptors in the mouse retina,” *Journal of Neuroscience Research*, vol. 99, no. 12, pp. 3103–3120, 2021.

[50] M. Djerbi, T. Darreh-Shori, B. Zhivotovsky, and A. Grandien, “Characterization of the human FLICE-inhibitory protein locus and comparison of the anti-apoptotic activity of four different flip isoforms,” *Scandinavian Journal of Immunology*, vol. 54, no. 1–2, pp. 180–189, 2001.
[51] C. Plaza-Sirvent, M. Schuster, Y. Neumann et al., “c-FLIP expression in foxp3-expressing cells is essential for survival of regulatory T cells and prevention of autoimmunity,” Cell Reports, vol. 18, no. 1, pp. 12–22, 2017.

[52] A. R. Safa, “c-FLIP, a master anti-apoptotic regulator,” Experimental Oncology, vol. 34, no. 3, pp. 176–184, 2012.

[53] A. Lees, A. J. McIntyre, N. T. Crawford et al., “The pseudocaspase FLIP(L) regulates cell fate following p53 activation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 117, no. 30, pp. 17808–17819, 2020.

[54] F. C. Kischkel, S. Hellbardt, I. Behrmann et al., “Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor,” The EMBO Journal, vol. 14, no. 22, pp. 5579–5588, 1995.

[55] C. Pop, A. Oberst, M. Drag et al., “FLIPL induces caspase 8 activity in the absence of interdomain caspase 8 cleavage and alters substrate specificity,” The Biochemical Journal, vol. 433, no. 3, pp. 447–457, 2011.

[56] I. N. Lavrik, “Systems biology of death receptor networks: live and let die,” Cell Death & Disease, vol. 5, no. 5, article e1259, 2014.

[57] A. Kaunisto, V. Kochin, T. Asaoka et al., “PKC-mediated phosphorylation regulates c-FLIP ubiquitylation and stability,” Cell Death and Differentiation, vol. 16, no. 9, pp. 1215–1226, 2009.